Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 29 Mar 2017 Planned number of patients changed from 802 to 1316.
- 18 Oct 2016 Planned number of patients changed from 520 to 802.
- 18 Jul 2016 Planned number of patients changed from 3000 to 520.